These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 17766459)
1. Fate of the two-component lantibiotic lacticin 3147 in the gastrointestinal tract. Gardiner GE; Rea MC; O'Riordan B; O'Connor P; Morgan SM; Lawlor PG; Lynch PB; Cronin M; Ross RP; Hill C Appl Environ Microbiol; 2007 Nov; 73(21):7103-9. PubMed ID: 17766459 [TBL] [Abstract][Full Text] [Related]
2. Fate and efficacy of lacticin 3147-producing Lactococcus lactis in the mammalian gastrointestinal tract. Dobson A; Crispie F; Rea MC; O'Sullivan O; Casey PG; Lawlor PG; Cotter PD; Ross P; Gardiner GE; Hill C FEMS Microbiol Ecol; 2011 Jun; 76(3):602-14. PubMed ID: 21314706 [TBL] [Abstract][Full Text] [Related]
3. Pharmaceutical design of a delivery system for the bacteriocin lacticin 3147. Ryan A; Patel P; O'Connor PM; Ross RP; Hill C; Hudson SP Drug Deliv Transl Res; 2021 Aug; 11(4):1735-1751. PubMed ID: 33876405 [TBL] [Abstract][Full Text] [Related]
4. Bioavailability of the anti-clostridial bacteriocin thuricin CD in gastrointestinal tract. Rea MC; Alemayehu D; Casey PG; O'Connor PM; Lawlor PG; Walsh M; Shanahan F; Kiely B; Ross RP; Hill C Microbiology (Reading); 2014 Feb; 160(Pt 2):439-445. PubMed ID: 24287693 [TBL] [Abstract][Full Text] [Related]
5. Sequential actions of the two component peptides of the lantibiotic lacticin 3147 explain its antimicrobial activity at nanomolar concentrations. Morgan SM; O'connor PM; Cotter PD; Ross RP; Hill C Antimicrob Agents Chemother; 2005 Jul; 49(7):2606-11. PubMed ID: 15980326 [TBL] [Abstract][Full Text] [Related]
6. In vitro antimicrobial effect and in vivo preventive and therapeutic effects of partially purified lantibiotic lacticin NK34 against infection by Staphylococcus species isolated from bovine mastitis. Kim SY; Shin S; Koo HC; Youn JH; Paik HD; Park YH J Dairy Sci; 2010 Aug; 93(8):3610-5. PubMed ID: 20655430 [TBL] [Abstract][Full Text] [Related]
7. Single versus double occupancy solid lipid nanoparticles for delivery of the dual-acting bacteriocin, lacticin 3147. Ryan A; Patel P; O'Connor PM; Cookman J; Ross RP; Hill C; Hudson SP Eur J Pharm Biopharm; 2022 Jul; 176():199-210. PubMed ID: 35640784 [TBL] [Abstract][Full Text] [Related]
8. Structural characterization of lacticin 3147, a two-peptide lantibiotic with synergistic activity. Martin NI; Sprules T; Carpenter MR; Cotter PD; Hill C; Ross RP; Vederas JC Biochemistry; 2004 Mar; 43(11):3049-56. PubMed ID: 15023056 [TBL] [Abstract][Full Text] [Related]
9. Complete alanine scanning of the two-component lantibiotic lacticin 3147: generating a blueprint for rational drug design. Cotter PD; Deegan LH; Lawton EM; Draper LA; O'Connor PM; Hill C; Ross RP Mol Microbiol; 2006 Nov; 62(3):735-47. PubMed ID: 17076667 [TBL] [Abstract][Full Text] [Related]
10. Development of small intestinal enzyme activities and their relationship with some gut regulatory peptides in grazing sheep. Wang CL; Lang X; Wu PJ; Casper DP; Li FD J Anim Sci; 2017 Aug; 95(8):3783-3791. PubMed ID: 28805888 [TBL] [Abstract][Full Text] [Related]
11. Cross-immunity and immune mimicry as mechanisms of resistance to the lantibiotic lacticin 3147. Draper LA; Grainger K; Deegan LH; Cotter PD; Hill C; Ross RP Mol Microbiol; 2009 Feb; 71(4):1043-54. PubMed ID: 19183281 [TBL] [Abstract][Full Text] [Related]
12. A system for the random mutagenesis of the two-peptide lantibiotic lacticin 3147: analysis of mutants producing reduced antibacterial activities. Field D; Collins B; Cotter PD; Hill C; Ross RP J Mol Microbiol Biotechnol; 2007; 13(4):226-34. PubMed ID: 17827973 [TBL] [Abstract][Full Text] [Related]
13. The biology of lantibiotics from the lacticin 481 group is coming of age. Dufour A; Hindré T; Haras D; Le Pennec JP FEMS Microbiol Rev; 2007 Mar; 31(2):134-67. PubMed ID: 17096664 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological activity of oxa-lacticin A2, a lantibiotic analogue with sulfur replaced by oxygen. Liu H; Pattabiraman VR; Vederas JC Org Lett; 2009 Dec; 11(24):5574-7. PubMed ID: 19921853 [TBL] [Abstract][Full Text] [Related]
15. Effect of a negatively charged lipid on membrane-lacticin Q interaction and resulting pore formation. Yoneyama F; Shioya K; Zendo T; Nakayama J; Sonomoto K Biosci Biotechnol Biochem; 2010; 74(1):218-21. PubMed ID: 20057115 [TBL] [Abstract][Full Text] [Related]
16. Effect of bioengineering lacticin 3147 lanthionine bridges on specific activity and resistance to heat and proteases. Suda S; Westerbeek A; O'Connor PM; Ross RP; Hill C; Cotter PD Chem Biol; 2010 Oct; 17(10):1151-60. PubMed ID: 21035738 [TBL] [Abstract][Full Text] [Related]
17. Impact of the broad-spectrum antimicrobial peptide, lacticin 3147, on Streptococcus mutans growing in a biofilm and in human saliva. Dobson A; O'Connor PM; Cotter PD; Ross RP; Hill C J Appl Microbiol; 2011 Dec; 111(6):1515-23. PubMed ID: 21923747 [TBL] [Abstract][Full Text] [Related]
18. Solid supported chemical syntheses of both components of the lantibiotic lacticin 3147. Liu W; Chan AS; Liu H; Cochrane SA; Vederas JC J Am Chem Soc; 2011 Sep; 133(36):14216-9. PubMed ID: 21848315 [TBL] [Abstract][Full Text] [Related]
19. Spontaneous resistance in Lactococcus lactis IL1403 to the lantibiotic lacticin 3147. Guinane CM; Cotter PD; Hill C; Ross RP FEMS Microbiol Lett; 2006 Jul; 260(1):77-83. PubMed ID: 16790021 [TBL] [Abstract][Full Text] [Related]
20. Maturation by LctT is required for biosynthesis of full-length lantibiotic lacticin 481. Uguen P; Hindré T; Didelot S; Marty C; Haras D; Le Pennec JP; Vallée-Réhel K; Dufour A Appl Environ Microbiol; 2005 Jan; 71(1):562-5. PubMed ID: 15640237 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]